Entera Bio outlined three near-term milestones: submission of a final Phase 3 protocol to FDA for EB613, its oral PTH(1-34) anabolic tablet for postmenopausal osteoporosis, by the end of the first quarter of 2026; top-line results from a Phase 1 bridging study of a next-generation EB613 formulation in the same timeframe; and accelerated clinical entry in 2026 for EB612, an oral long-acting PTH program for hypoparathyroidism. The plans follow FDA alignment on EB613 in July 2025 and the agency’s December 19, 2025 broad qualification of bone mineral density as a regulatory endpoint for anti-osteoporosis drugs, creating a clearer pathway for a potentially first-in-class oral anabolic.
The FDA’s endorsement of BMD as a qualified endpoint reshapes the development calculus in osteoporosis. If BMD can anchor pivotal evidence, Phase 3 programs could become faster, smaller, and less expensive, altering the risk-reward for oral biologics. The strategic question is whether a BMD-driven approval will be sufficient for market adoption of an oral teriparatide in a landscape where payers and guidelines often privilege fracture reduction and real-world persistence.
For patients and prescribers, the stakes are meaningful. An oral anabolic could expand use beyond the niche carved out by daily injections, bringing bone-building therapy earlier in the treatment sequence for high-risk women who avoid needles or struggle with persistence. For Medical Affairs, the job will be to translate surrogate-driven evidence into clinical confidence, with pragmatic data on adherence, persistence, and downstream fracture outcomes likely crucial for payer contracts and guideline inclusion. Commercial teams will need to position convenience and potential persistence benefits against entrenched, lower-cost options, including generic teriparatide injections, bisphosphonates, and newer agents like romosozumab, and to quantify the value of moving an anabolic upstream. If the next-generation EB613 improves administration requirements or variability, it could meaningfully strengthen the value proposition, but those details will matter as much as headline efficacy.
Hypoparathyroidism may offer an even sharper edge. The withdrawal of PTH 1-84 from the U.S. market left a therapeutic void, with many patients reliant on calcium and active vitamin D or off-label use of short-acting agents. A long-acting oral PTH replacement could be the first scalable, injection-free option, with endpoints centered on maintaining normocalcemia, reducing supplement burden, and improving quality of life. Payers will scrutinize durability, safety, and resource utilization, making early health-economic modeling and targeted RWE essential. For HCPs managing brittle disease courses, a reliable oral profile could reset the standard of care if variability and dosing logistics are well controlled.
The move also fits a broader industry arc: the renaissance of oral peptides and proteins, the validation of delivery platforms, and the pragmatic turn toward surrogate endpoints to compress timelines. Smaller platform companies are leaning into selective late-stage pushes while courting partners to shoulder commercialization, and 2026 looks set to reward assets that can show a de-risked regulatory path and a clean commercial story. Entera’s concurrent bridging study suggests attention to the operational realities that make or break oral biologics, from fasting windows to manufacturing scalability.
What to watch next is whether the Phase 3 design leans on BMD alone or incorporates fracture-related outcomes to preempt payer resistance, how the next-generation tablet simplifies real-world use, and whether partnership signals emerge ahead of pivotal start. The central test is not just regulatory feasibility but commercial credibility: will a BMD-qualified, truly convenient oral anabolic be enough to shift treatment behavior and unlock access at scale?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
